- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07588711
Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) as an Anti-inflammatory Strategy for the Treatment of Neuropathic Pain Following Spinal Cord Injury
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Neuropathic pain is a common and debilitating complication following spinal cord injury (SCI) and is frequently resistant to pharmacologic treatment. Chronic neuroinflammation and reduced vagal tone are increasingly recognized contributors to persistent neuropathic pain after SCI. The vagus nerve plays a central role in immune regulation and descending pain modulation.
Transcutaneous auricular vagus nerve stimulation (taVNS) is a noninvasive neuromodulation technique that stimulates vagal afferent fibers via the external ear. Prior Health Canada-authorized trials conducted by the investigative team have demonstrated the feasibility, safety, and autonomic effects of taVNS in individuals with SCI.
This single-site, randomized, double-blind, sham-controlled pilot study will enroll 32 adults with SCI and neuropathic pain. Participants will be randomized 1:1 to receive either active or sham taVNS for 4 hours per day over a 30-day home-based intervention period. Outcomes will be assessed at baseline and immediately post-intervention. Feasibility and safety outcomes are primary, while exploratory clinical and mechanistic outcomes will inform the design of a future definitive randomized controlled trial.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: David J Allison, PhD.
- Telefonnummer: 42570 519 646 6100
- E-mail: David.Allison@sjhc.london.on.ca
Undersøgelse Kontakt Backup
- Navn: Joy Jiang
- Telefonnummer: 42570 519 646 6100
- E-mail: fjiang63@uwo.ca
Studiesteder
-
-
Ontario
-
London, Ontario, Canada, N6C0A7
- Parkwood Institute, St Joseph's Health Care London
-
Kontakt:
- Joy Jiang
- Telefonnummer: 42570 519 646 6100
- E-mail: fjiang63@uwo.ca
-
Kontakt:
- David J. Allison, PhD
- Telefonnummer: 42570 519 646 6100
- E-mail: David.Allison@sjhc.london.on.ca
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- SCI of any level or severity
- 18 years of age or older
- current neuropathic pain
- on no medications or on a stable prescribed dose (no change in prior 6-weeks) of anti-inflammatory, pain medications and/or depression medications
Exclusion Criteria:
- Prone to autonomic dysreflexia
- presence of cardiovascular disease
- pacemaker or other implanted electrical device
- cerebral shunts
- epilepsy
- pregnant or attempting to become pregnant
- current wound/infection
- unstable dose of prescribed anti-inflammatory, depression, or pain medications within past 6-weeks.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Active taVNS
Participants receive active transcutaneous auricular vagus nerve stimulation delivered via the cymba conchae of the left ear using the using the tVNS R device (taVNS Technologies, Erlangen, Germany) for 4 hours per day for 30 days.
|
Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the tVNS R device (taVNS Technologies, Erlangen, Germany).
To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA (milliamps) until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA).
Pulse width will be set at 100μs (microseconds) and frequency will be set at 25Hz (Hertz).
Parameters will be set for the duration of the intervention consisting of 4 hours of daily stimulation for a period of 30 days.
|
|
Sham-komparator: Sham taVNS
Stimulation will target the ear lobe using the tVNS R device (taVNS Technologies, Erlangen, Germany) for 4 hours per day for 30 days.
Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
|
Stimulation will target the ear lobe using the tVNS R device (taVNS Technologies, Erlangen, Germany).
To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA).
Pulse width will be set at 100μs and frequency will be set at 25Hz.
Participants will perform 4 hours of stimulation per day for a period of 30 days.
Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Forekomst af behandlings-opståede uønskede hændelser under intervention
Tidsramme: 30 dage
|
Alle uønskede hændelser, der opstår under interventionen, vil blive registreret under de to gange ugentlige telefonopkald og/eller studiebesøg og sammenlignet mellem de aktive taVNS- og sham-taVNS-tilstande.
En beskrivelse af den uønskede hændelse, antallet af hændelser og det samlede antal berørte deltagere vil blive registreret.
|
30 dage
|
|
Success of Participant and Investigator Blinding
Tidsramme: Day 30
|
Blinding success will be assessed after completion of the intervention by asking participants and investigators to indicate which treatment group they believe the participant was assigned to (active taVNS or sham taVNS).
Blinding effectiveness will be quantified using the James Blinding Index, calculated separately for participants and investigators.
Blinding outcomes will be summarized descriptively.
|
Day 30
|
|
Recruitment Rate and Time to Recruit Target Sample Size
Tidsramme: Up to 20 months
|
Recruitment feasibility will be assessed by documenting the number and proportion of eligible individuals who consent to participate and the total time required to recruit the target sample of 32 participants.
Recruitment rate will be calculated as the percentage of eligible candidates who agree to participate.
These data will be summarized descriptively for the overall study population.
|
Up to 20 months
|
|
Retention and Attrition During the 30-Day Intervention
Tidsramme: 30 days
|
Retention will be assessed as the proportion of enrolled participants who complete the full 30-day intervention and post-intervention assessment.
Attrition will be recorded as the number and proportion of participants who withdraw prior to study completion.
Reasons for withdrawal or loss to follow-up will be documented where available.
Retention and attrition rates will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
|
30 days
|
|
Adherence to Daily taVNS Stimulation Prescription
Tidsramme: 30 days
|
Adherence will be assessed using automated usage data recorded by the taVNS device and associated smartphone application.
Daily adherence will be calculated as the percentage of the prescribed 4-hour daily stimulation period completed (actual stimulation time divided by prescribed stimulation time × 100).
Overall adherence will be summarized as the mean daily adherence across the 30-day intervention period.
Adherence will be compared descriptively between the active taVNS and sham taVNS groups.
|
30 days
|
|
Acceptability with the taVNS intervention
Tidsramme: Day 30
|
Participant acceptability will be assessed at the end of the intervention using the Acceptability of Intervention Measure (AIM).
Acceptability scores will be summarized descriptively and compared between the active taVNS and sham taVNS conditions.
|
Day 30
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Circulating C-Reactive Protein
Tidsramme: Baseline and Day 30
|
Plasma concentrations of C-reactive protein (CRP) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in milligrams per liter (mg/L), with higher values indicating greater systemic inflammation.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Interleukin-1 Beta
Tidsramme: Baseline and Day 30
|
Plasma concentrations of interleukin-1 beta (IL-1β) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Interleukin-6
Tidsramme: Baseline and Day 30
|
Plasma concentrations of interleukin-6 (IL-6) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Interferon Gamma
Tidsramme: Baseline and Day 30
|
Plasma concentrations of interferon gamma (IFN-γ) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Tumor Necrosis Factor Alpha
Tidsramme: Baseline and Day 30
|
Plasma concentrations of tumor necrosis factor alpha (TNF-α) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Neuropathic Pain Assessed by the Neuropathic Pain Symptoms Inventory
Tidsramme: Baseline and Day 30
|
Neuropathic pain severity and interference will be assessed using the Neuropathic Pain Symptoms Inventory (NPSI), a self-reported questionnaire with total scores ranging from 0 to 100, where higher scores indicate greater neuropathic pain severity and pain-related interference.
Change scores will be calculated as post-intervention values minus baseline values.
Mean changes and variability will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Neuropathic Pain Assessed by the International Spinal Cord Injury Pain Basic Data Set (version 3)
Tidsramme: Baseline and Day 30
|
Neuropathic pain severity and pain-related interference will be assessed using the International Spinal Cord Injury Pain Basic Data Set (ISCIPBDS), version 3, which includes numeric rating scales ranging from 0 to 10, where higher scores indicate greater pain intensity and greater pain-related interference.
Change scores will be calculated as post-intervention values minus baseline values.
Mean changes and variability will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Vagal Tone Assessed by Heart Rate Variability
Tidsramme: Baseline and Day 30
|
Vagal tone will be assessed using heart rate variability (HRV) derived from a 5-minute resting electrocardiogram recording.
Root mean square of successive differences (RMSSD) and high-frequency power will be calculated using standard HRV analysis procedures.
Change in HRV measures from baseline to post-intervention will be summarized descriptively and compared between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Health-Related Quality of Life
Tidsramme: Baseline and Day 30
|
Quality of life will be assessed using selected short forms from the Spinal Cord Injury-Quality of Life (SCI-QOL) measurement system, including Pain Interference, Depression, and Positive Affect and Well-Being domains.
Scores will be calculated as standardized T-scores.
Change in quality-of-life scores from baseline to post-intervention will be summarized and compared descriptively between treatment groups.
|
Baseline and Day 30
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Smerte
- Neurologiske manifestationer
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Sår og skader
- Patologiske processer
- Neuromuskulære sygdomme
- Sygdomme i det perifere nervesystem
- Traumer, nervesystemet
- Rygmarvssygdomme
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Betændelse
- Neuralgi
- Rygmarvsskader
Andre undersøgelses-id-numre
- ALLISON-03-2026
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .